Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline of talk
- Mitomycin properties
- Mode of action
- Mitomycin C is inactive in its quinone form
- Basis of the reductive activation of mitomycins
- The mitomycin "reductive activation cascade"
- Leuco-aziridinomitosene may decay by reoxidation
- O2 inhibits the first step of reductive activation
- Concept of bioreductive anticancer drugs: Sartorelli
- Reaction products of mitomycins with DNA
- Isolation of reaction products of mitomycin C
- Isolation of a fourth adduct
- Structures of the adducts
- Sequence recognition in the first alkylation step
- Mechanism of the CG*CG recognition selectivity
- Proof of the proposed minor groove alignment
- Molecular recognition of DNA sequence
- CpG or GpC cross-links?
- Orientation of the intermediate monoadduct
- Molecular evolution
- Mitomycin C selectively recognizes 5-methyl CpG
- Why does MC alkylate preferentially guanines?
- 5-fluoro-C substitution has opposite effect
- Further evidence of the hypothesis
- Significance of special recognition of 5-methyl C*G
- DNA adducts formed in vivo
- Major metabolic fate of MC: reduction to 2,7-DAM
- 2,7-DAM adducts in MC- & 2,7-DAM-treated cells
- Models of minor and major groove monoadducts
- Biological activity of 2,7-DAM and its DNA adducts
- Large array of different adducts
- Structure-function relationships of DNA adducts
- Individual adducts selective introduction in the cell
- The dG-2,7-DAM 5 adduct is not mutagenic
- Neither adduct 1a nor adduct 5 is mutagenic
- What is the basis for the different cytotoxicities?
- Differential blockage of replication?
- MC monoadduct blocks Klenow DNA polymerase
- T-7 exo- polymerase by-passes 2,7-DAM
- MC monoadduct blocks T-7 exo- DNA polymerase
- Single nucleotide incorporation
- Conclusions from in vitro primer extension study
- Other studies of mitomycins in our laboratory
- References
Topics Covered
- The mitomycins: structures, properties, early research of the molecular basis of biological activity
- Reductive activation
- Chemistry of the interactions with DNA: DNA adducts, cross-linking of DNA
- Molecular recognition of DNA
- Metabolic chemistry
- Structure/activity relationships of the DNA adducts
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tomasz, M. (2008, August 14). Drug-DNA interactions of the mitomycins [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/PYOW3340.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Maria Tomasz has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.